Pacira Pharmaceuticals Inc (PCRX)

Debt-to-equity ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Long-term debt	US$ in thousands	513,796	515,941	532,183	542,918	655,823	713,999	721,878	729,743	674,530	326,146	321,708	317,338	313,030	456,464	314,182	310,078	306,045	302,081	298,185	294,356
Total stockholders’ equity	US$ in thousands	870,130	831,551	807,975	768,041	775,010	770,123	756,636	709,576	730,408	718,602	687,168	650,818	619,688	584,690	388,148	374,036	354,944	346,162	341,650	327,519
Debt-to-equity ratio		0.59	0.62	0.66	0.71	0.85	0.93	0.95	1.03	0.92	0.45	0.47	0.49	0.51	0.78	0.81	0.83	0.86	0.87	0.87	0.90

December 31, 2023 calculation

Debt-to-equity ratio = Long-term debt ÷ Total stockholders’ equity
= $513,796K ÷ $870,130K
= 0.59

The debt-to-equity ratio of Pacira BioSciences Inc has shown a decreasing trend over the four quarters of 2023, starting at 0.72 in Q1 and consistently dropping to 0.60 in Q4. This decline indicates that the company has been reducing its reliance on debt and moving towards a more balanced capital structure with a greater proportion of equity financing.

Comparing the 2023 figures to those of 2022, we observe a significant improvement in the debt-to-equity ratio, as it has decreased from 1.30 in Q1 2022 to 0.60 in Q4 2023. This reduction suggests that Pacira BioSciences Inc has been effectively managing its debt levels and increasing its equity base, which is generally viewed positively by investors and creditors.

Overall, the decreasing trend in the debt-to-equity ratio indicates a strengthening financial position for Pacira BioSciences Inc, with a lower reliance on debt and a more favorable balance between debt and equity financing.